Search | Clinical Trials Finder

Conditions: Nutraceuticals
Interventions: Betalain-rich concentrate (AltRed), Placebo; Dietary Supplement · Other
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Placebo and fMRI, Naltrexone and fMRI; Combination Product
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: MPOX
Interventions: Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more

Conditions: Pulmonary Arterial Hypertension
Interventions: DHEA tablet, Placebo; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Postural Tachycardia Syndrome
Interventions: placebo sugar pill, Pyridostigmine Pill, Galantamine Pill, Vagal stimulation, Sham vagal stimulation; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, PF-06882961; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Anaheim, California • South Miami, Florida • Overland Park, Kansas

Conditions: Type 2 Diabetes
Interventions: dapagliflozin, placebo, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 111
States / cities: Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 45 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: San Francisco, California • San Jose, California • Stanford, California + 5 more

Conditions: Parkinsons Disease
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Daniel Burdick, MD; Individual
Eligibility: 30 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: HCV Infection
Interventions: EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more

Conditions: Hyperphagia in Prader-Willi Syndrome
Interventions: FE 992097, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Gainesville, Florida • Mineola, New York • Nashville, Tennessee

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Conditions: Alcoholism
Interventions: Topiramate and Naltrexone, Placebo; Drug · Other
Lead sponsor: Bankole Johnson; Other
Eligibility: 21 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions: quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy; Drug · Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Restless Legs Syndrome
Interventions: Pregabalin (Lyrica), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Schizophrenia
Interventions: Placebo, Bitopertin, Antipsychotics; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 27
States / cities: Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more

Conditions: Female Sexual Health
Interventions: Sildenafil; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Paclitaxel, BKM120 matching placebo, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more

Conditions: Bladder Cancer
Interventions: SUTENT, Placebo; Drug · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more

Conditions: Partial Onset Seizures
Interventions: BGG492; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: Schizophrenia
Interventions: Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 39
States / cities: Cerritos, California • Escondido, California • Garden Grove, California + 31 more

Conditions: Depression, Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Interventions: Sertraline (Zoloft), Simvastatin (Zocor); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.

Food Reward in Native American Women

Study of Tecovirimat for Human Mpox Virus

Effects of DHEA in Pulmonary Hypertension

Vagal Stimulation in POTS

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Treatment of Supine Hypertension in Autonomic Failure

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study

Quetiapine for the Reduction of Cocaine Use

Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

Phase II BGG492 Capsule Extension for Partial Epilepsy

Trial of Indomethacin in Chronic Pancreatitis

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease